| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | Controlling magnetic nanoparticles to increase vascular flow | US14020173 | 2013-09-06 | US08926491B2 | 2015-01-06 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 162 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF | US14342164 | 2012-09-07 | US20140212406A1 | 2014-07-31 | Denis Viven; Jerome Parcq |
| The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | ||||||
| 163 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE | US14151390 | 2014-01-09 | US20140199287A1 | 2014-07-17 | Mariola SOHNGEN; Wolfgang SOHNGEN; Wolf-Dieter SCHLEUNING; Robert MEDCALF |
| The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 164 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF | US13627555 | 2012-09-26 | US20140088009A1 | 2014-03-27 | Byron D. Ford; James W. Lillard, JR. |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
| 165 | PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE | US13993297 | 2011-12-16 | US20130323227A1 | 2013-12-05 | Maheshwari Kumar Mishra; Sanjay Singh; Pritiranjan Bhandari |
| Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke. | ||||||
| 166 | Methods of controlling magnetic nanoparticles to improve vascular flow | US13485613 | 2012-05-31 | US08529428B2 | 2013-09-10 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 167 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques | US13641375 | 2011-04-14 | US20130195828A1 | 2013-08-01 | Melina R. Kibbe; Guillermo A. Ameer; Vinit N. Varu |
| Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | ||||||
| 168 | GELATINASE INHIBITORS AND PRODRUGS | US13582678 | 2011-03-04 | US20130052184A1 | 2013-02-28 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 169 | METHODS OF CONTROLLING MAGNETIC NANOPARTICLES TO IMPROVE VASCULAR FLOW | US13485613 | 2012-05-31 | US20120296149A1 | 2012-11-22 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 170 | Magnetic-based systems for treating occluded vessels | US13471871 | 2012-05-15 | US08308628B2 | 2012-11-13 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 171 | Non-neurotoxic plasminogen activating factors for treating of stroke | US12196785 | 2008-08-22 | US08119597B2 | 2012-02-21 | Mariola Sohngen; Wolfgang Sohngen; Wolf-Dieter Schleuning; Robert Medcalf |
| The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 172 | USE OF MATRIX METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC TREATMENTS | US12861357 | 2010-08-23 | US20110091436A1 | 2011-04-21 | Josune Orbe Lopategui; Jose Antonio Rodriguez Garcia; Jose Antonio Paramo Fernandez; Rosario Serrano Vargas |
| The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders. | ||||||
| 173 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE | US12196785 | 2008-08-22 | US20090263373A1 | 2009-10-22 | Mariola SOHNGEN; Wolfgang Sohngen; Wolf-Dieter Schleuning; Robert Medcalf |
| The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 174 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE | US12163828 | 2008-06-27 | US20090004176A1 | 2009-01-01 | Robert MEDCALF; Mariola Sohngen; Wolfgang Sohngen; Wolf-Dieter Schleuning |
| The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans. | ||||||
| 175 | PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS | US11533305 | 2006-09-19 | US20070014779A1 | 2007-01-18 | Charles Semba |
| A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution. | ||||||
| 176 | Non-neurotoxic plasminogen activating factors for treating of stroke | US11311475 | 2005-12-20 | US20060142195A1 | 2006-06-29 | Robert Medcalf |
| The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans. | ||||||
| 177 | Non-neurotoxic plasminogen activating factors for treating stroke | US10494004 | 2002-10-31 | US20050048027A1 | 2005-03-03 | Mariola Sohngen; Wolfgang Sohngen; Wolf-Dieter Schleuning; Robert Medcalf |
| The invention concerns the use and the production of non-neurotoxin plasminogen activating factors, derived for example from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 178 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US09492011 | 2000-01-26 | US06306922B1 | 2001-10-23 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 179 | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers | US700237 | 1996-08-20 | US5986043A | 1999-11-16 | Jeffrey A. Hubbell; Chandrashekhar P. Pathak; Amarpreet S. Sawhney; Neil P. Desai; Jennifer L. Hill-West |
| Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue surfaces. | ||||||
| 180 | Genetic modification of endothelial cells | US249092 | 1994-05-25 | US5674722A | 1997-10-07 | Richard C. Mulligan; Lawrence K. Cohen; Lori F. Rafield; Louis K. Birinyi; Allan D. Callow; James M. Wilson |
| Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual. | ||||||
QQ群二维码
意见反馈
意见反馈